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Abstract The National Institute for Health and Care
Excellence (NICE) invited Janssen, the company manu-
facturing abiraterone acetate (AA; tradename Zytiga), to
submit evidence for the clinical and cost effectiveness of
AA in combination with prednisone/prednisolone (AAP)
compared with watchful waiting (i.e. best supportive care
[BSC]) for chemotherapy-naı¨ve patients with metastatic
castration-resistant prostate cancer (mCRPC). Kleijnen
Systematic Reviews Ltd (KSR), in collaboration with
Maastricht University Medical Center, was commissioned
as the Evidence Review Group (ERG). This paper presents
a summary of the company submission (CS), the ERG
report, subsequent addenda, and the development of the
NICE guidance for the use of this drug in England and
Wales by the Appraisal Committee (AC). The ERG pro-
duced a critical review of the clinical and cost effectiveness
of AAP based on the CS. An important question in this
appraisal was, according to the ERG, whether AAP fol-
lowed by docetaxel is more effective than BSC followed by
docetaxel. In the COU-AA-302 trial, 239 of 546 (43.8 %)
AAP patients and 304 of 542 (56.1 %) BSC patients
received docetaxel as subsequent therapy, following AA or
placebo. The results for this specific group of patients were
not presented in the CS; therefore, the ERG asked the
company to provide these data in the clarification letter;
however, these data were presented as commercial-in-
confidence and cannot therefore be reported here. The
ERG’s critical assessment of the company’s economic
evaluation highlighted a number of concerns, including
(a) not using the intention-to-treat (ITT) population;
(b) inconsistencies in estimating prediction equations;
(c) not fully incorporating the impact of adverse events;
(d) incorrectly incorporating the new patient access
scheme (PAS); and (e) the assumption that AA non-com-
pliance leads to recoverable drug costs. Although some of
these issues were adjusted in the ERG base case, the ERG
could not estimate the impact of all of these issues, and
thus acknowledges that there are still uncertainties con-
cerning the cost-effectiveness evidence. With the exception
of the ERG’s preference for using the ITT population, the
AC agreed with the approach taken in the ERG base case.
The original company and ERG base-case incremental
cost-effectiveness ratios (ICERs) were £46,722 and
£57,688 per QALY gained, respectively; these changed to
£28,563 and £38,061 per QALY gained, respectively, in
the revised base cases applying a new PAS. Regarding the
end-of-life criteria, after 24 months approximately 63 % of
patients in the control group of the COU-AA-302 trial were
still alive, and the median survival was 30.1 months (95 %
CI 27.3–34.1). Therefore, it is unlikely that life expectancy
would be less than 24 months. The AC stated that the most
plausible ICER is likely between £28,600 and £32,800 per
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QALY gained, and concluded that AAP at this stage in the
treatment pathway did not meet the end-of-life criterion for
short life expectancy. Moreover, in March 2016, the AC
produced the final guidance, stating that AAP is recom-
mended, within its marketing authorisation, as an option
for treating mCRPC.
Key Points for Decision Makers
Abiraterone acetate (tradename Zytiga) in
combination with prednisone/prednisolone (AAP)
delays clinical disease progression and initiation of
chemotherapy compared with best supportive care in
chemotherapy-naı¨ve patients with metastatic
castration-resistant prostate cancer (mCRPC).
Typically, the ITT population is preferred to
populate the economic model; however, in this
specific case, the National Institute for Health and
Care Excellence (NICE) Appraisal Committee
preferred a selected subpopulation (complete cases).
Multiple patient access schemes (PASs) for the same
drug might be used in the economic model if the
drug is used in different disease stages.
Potential administration costs of complex PASs
should be incorporated in the cost-effectiveness
estimates.
The NICE Appraisal Committee has recommended
AAP within its licenced indication as an option for
treating mCRPC in people who have no or mild
symptoms after androgen deprivation therapy has
failed, and before chemotherapy is indicated.
1 Introduction
Health technologies must be shown to be clinically effec-
tive and to represent a cost effective use of National Health
Service (NHS) resources in order to be recommended by
the National Institute for Health and Care Excellence
(NICE) for use within the NHS in England and Wales.
NICE is an independent organisation responsible for pro-
viding national guidance on promoting good health and
preventing and treating ill health in priority areas with a
significant impact. The NICE single technology appraisal
(STA) process typically considers new technologies within
a single indication [1]. Within the STA process, the com-
pany provides NICE with a written submission, including
an executable health economic model, considering the
company’s estimates of the clinical effectiveness and cost
effectiveness of the technology. This company submission
(CS) is critically reviewed by the Evidence Review Group
(ERG), an external organisation independent of NICE,
which produces an ERG report. After consideration of the
CS, the ERG report, and testimony from experts and other
stakeholders, the NICE Appraisal Committee (AC) for-
mulates the Appraisal Consultation Document (ACD),
which contains preliminary guidance regarding the initial
decision on whether or not to recommend the technology.
Subsequently, stakeholders are invited to comment on the
submitted evidence and the ACD, after which a subsequent
ACD may be produced or a Final Appraisal Determination
(FAD) is issued, which is open to appeal.
This paper presents a summary of the CS [2], the ERG
report [3], subsequent addenda [4] for the STA on abi-
raterone acetate (AA; tradename: Zytiga) in combination
with prednisone/prednisolone (AAP) for the treatment of
chemotherapy-naı¨ve metastatic castration-resistant prostate
cancer (mCRPC), and the subsequent development of the
NICE guidance. All relevant documents are publically
available online [4]. AAP has previously been recom-
mended by NICE for the treatment of mCRPC previously
treated with docetaxel-containing chemotherapy (STA259)
[5].
2 The Decision Problem
The patient population described in the final scope, speci-
fied by NICE [6], is ‘‘Adults with mCRPC who are
asymptomatic or mildly symptomatic after failure of
androgen deprivation therapy (ADT) in whom
chemotherapy is not yet clinically indicated’’.
In the early stages, prostate cancer is localised to the
prostate gland and can be managed with active surveil-
lance, surgical removal of the prostate (i.e. prostatectomy)
or radical radiotherapy with or without ADT [7]. How-
ever, it may slowly progress to a chronic stage and over a
period of time can rapidly progress to a more advanced/
metastatic stage [2]. It is estimated that 55–65 % of
prostate cancer patients will develop metastatic disease
[6]. Available treatments for metastatic prostate cancer
include surgical castration or ADT to reduce the testos-
terone levels, which helps in slowing down the tumour
growth and delays progression. Nevertheless, after
1–2 years the tumour typically stops responding to the
castration therapy and resumes growth [2]; this is termed
‘castration-resistant’ prostate cancer. The patients diag-
nosed with ‘castration-resistant’ prostate cancer are likely
to be metastatic (i.e. mCRPC), meaning the tumour has
spread outside the prostate. According to the CS [2], it
192 B. L. T. Ramaekers et al.
was traditionally thought that tumours grow during ADT
because they became ‘hormone-refractory’ or ‘androgen-
independent’. However, current knowledge indicates that
these tumours still rely on hormones such as testosterone
for their growth, but are dependent on alternative sources
(e.g. adrenal cortex and synthesis within the tumour itself)
[2, 8]. For mCRPC, docetaxel is recommended as a
treatment option for hormone-refractory prostate cancer
associated with a Karnofsky performance status score of
60 % or more [7].
The company stated that the most common complaints
reported by symptomatic mCRPC patients included
lower extremity pain, loss of appetite and weight loss,
skeletal-related events (SREs), renal failure due to
obstruction of the urethra, and oedema due to obstruction
of venous and lymphatic tributaries by nodal metastases
[2, 9, 10].
When converted in vivo to abiraterone, AA is a selective
androgen biosynthesis that blocks cytochrome P17 (17a-
hydroxylase; an enzyme thought to play a role in the pro-
duction of testosterone), thereby stopping the testes and
other tissues in the body from making testosterone.
Treatment with AA therefore decreases serum testosterone
to undetectable levels, while ADT, such as luteinising
hormone-releasing hormone analogues, decrease androgen
production in the testes but do not affect androgen pro-
duction by the adrenals or in the tumour [2].
In December 2012, AA received a marketing authori-
sation from the European Medicines Agency (EMA) for the
treatment of mCRPC in adult men who are asymptomatic
or mildly symptomatic after failure of ADT in whom
chemotherapy is not yet clinically indicated. The recom-
mended dose is 1000 mg (single daily dose administered
orally) in combination with low-dose prednisone/pred-
nisolone (recommended dose 10 mg daily). The most
common adverse reactions seen are peripheral oedema,
hypokalaemia, hypertension and urinary tract infection.
Other important adverse reactions include cardiac disor-
ders, hepatotoxicity, fractures, and allergic alveolitis [11].
NICE issued a final scope [6] in January 2013 to
appraise the clinical and cost effectiveness of AAP within
its licensed indication for the treatment of chemotherapy-
naı¨ve mCRPC. At the time of submission, the scope stated
that the current relevant treatment options within the NHS
include docetaxel and best supportive care (BSC; may
include radiotherapy, radiopharmaceuticals, analgesics,
bisphosphonates, further hormonal therapies, and corti-
costeroids). Other subsequently licensed treatment options
were not considered relevant treatment options in this STA
(e.g. enzalutamide [tradename Xtandi], which is now
recommended [12]).
3 Independent Evidence Review Group Review
(ERG)
In February 2014, the company (Janssen) provided a sub-
mission to NICE on the clinical and cost effectiveness of
AAP within its licensed indication. In conformity with the
process for STAs, the company provided additional infor-
mation in response to clarification questions raised by the
ERG and NICE. Additionally, the ERG adjusted the deci-
sion analytic model received from the company to assess
the impact of alternative parameter values and assumptions
on the model results and to produce an ERG base case.
Sections 3.1–3.4 below summarises the evidence presented
in the CS, as well as the ERG’s review of that evidence.
Moreover, four addenda [4] submitted by the ERG (upon
request) in response to questions raised by the AC, to
additional data provided by the company and to a new
patient access scheme (PAS) submitted by the company,
are discussed. PASs typically reflect a discount on the list
price of a drug and are designed to ensure patients can gain
access to high-cost drugs.
3.1 Clinical-Effectiveness Evidence Submitted
by the Company
One randomised controlled trial (the COU-AA-302 trial
[13–15]) was included for the comparison of AAP versus
BSC. In the COU-AA-302 trial, a total of 1088 patients
were recruited and randomised to AAP (n = 546) or BSC
(i.e. placebo plus prednisone/prednisolone [PP]; n = 542).
Overall, 1082 patients received at least one dose of the
allocated intervention (safety population). Patients contin-
ued treatment with AAP or BSC until disease progression
(determined according to radiographic and clinical mea-
sures). The median treatment duration was 13.8 months (15
cycles initiated) in the AAP arm, and 8.3 months (nine
cycles initiated) in the BSC arm.
Results presented in the CS [2] were based on the results
from the second (data cut-off 20 December 2011) and third
(data cut-off 22 May 2012) interim analyses of the COU-
AA-302 study [13–15], which were conducted after
approximately 40 and 55 % of the total overall survival
(OS) events had occurred. Neither the second nor third
interim analysis OS results met the prespecified statistical
significance levels (hazard ratio [HR] at third interim
analysis 0.79; 95 % CI 0.66–0.96). Median OS was 35.3
months (95 % CI 31.2–35.3) in the AAP group and
30.1 months (95 % CI 27.3–34.1) in the PP group. The
company did not provide mean survival for both groups or
mean survival gain, despite explicit questions in the clari-
fication letter by the ERG [16].
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Treatment with AAP resulted in a 48 % relative
reduction in the risk of radiographic progression compared
with PP (absolute risk reduction 11.5 %), and increased
progression-free survival by 8.2 months. Significant dif-
ferences in favour of the AAP group were observed for
objective response rate (complete or partial response
according to modified Response Evaluation Criterita in
Solid Tumors [RECIST] criteria), prostate-specific antigen
response, and duration of response. Health-related quality
of life (HRQoL) was assessed in the COU-AA-302 study
via the Functional Assessment of Cancer Therapy–Prostate
(FACT–P) instrument; however, no results were reported
by treatment arm for baseline, follow-up, or change scores.
Time to progression in average pain intensity and worst
pain intensity showed no significant differences between
treatment arms. All other pain-related outcomes favoured
AAP over BSC.
Adverse events (AEs) were significantly more often
reported in the AAP arm when compared with the BSC arm
for treatment-emergent AEs (TEAEs); more specifically,
drug-related grade 3–4 TEAEs, treatment-emergent serious
AEs (SAEs), and grade 3–4 treatment-emergent SAEs. The
most frequently reported AEs were fatigue (39.7 % AAP
vs. 34.6 % PP), back pain (33.2 vs. 33.1 %), arthralgia
(29.3 vs. 24.4 %), nausea (24.0 vs. 23.0 %), peripheral
oedema (26.0 vs. 20.9 %), constipation (23.6 vs. 20.4 %),
diarrhoea (23.4 vs. 18.1 %), and hot flush (22.7 vs.
18.3 %). AAP resulted in significantly more grade 3 or 4
increased alanine transaminase, increased aspartate
aminotransferase, and dyspnoea, but less hydronephrosis.
3.2 Critique of Clinical Effectiveness Evidence
and Interpretation
Literature are available suggesting that docetaxel might be
less effective following AA [17]. Assuming that most
patients will end up using docetaxel, an important question
in this appraisal is whether AAP followed by docataxel is
more effective than watchful waiting (BSC) followed by
docetaxel. In the COU-AA-302 trial, 239 of 546 (43.8 %)
AAP patients and 304 of 542 (56.1 %) PP patients received
docetaxel as subsequent therapy. The results for this
specific group of patients are not presented in the CS but
were submitted by the company as part of the response to
the clarification letter; however, as these data were pro-
vided as commercial-in-confidence, we cannot report them
here.
According to the company, the Independent Data
Monitoring Committee for the COU-AA-302 trial con-
cluded on 27 February 2012 that patients in the AAP arm
had a ‘highly significant advantage’, even though the HR
for OS had not reached the stringent prespecified statistical
significance level (0.0034). The committee unanimously
recommended stopping the study, unblinding, and allowing
crossover. The study was unblinded on 2 April 2012, and
crossover from BSC to AAP occurred following unblinding
(2 April 2012) for three patients by the third interim
analysis (22 May 2012). Neither the second nor third
interim analysis OS results met the prespecified statistical
significance levels. Because crossover was now allowed, it
is unlikely that the trial will ever show a significant sur-
vival benefit.
3.3 Cost-Effectiveness Evidence Submitted
by the Company
The CS [2] included a literature search of relevant cost-
effectiveness studies; however, it did not identify any
studies on AAP for the treatment of adult men who were
asymptomatic or mildly symptomatic after failure of ADT
and in whom chemotherapy is not yet clinically indicated.
Therefore, a de novo economic analysis was performed by
the company.
The company presented a comparison of AAP versus
BSC by means of a discrete event simulation (DES) model,
tracking patients at the individual level. The model follows
patients until age 100 years, which is assumed to reflect a
lifetime time horizon. Patients entering the model (Fig. 1)
are assigned to either the AAP or the BSC strategy. Patients
who discontinue pre-docetaxel active treatment or progress
are monitored in a BSC phase before starting docetaxel.
After the docetaxel treatment phase, patients are monitored
in a BSC phase for progression again upon which they
could receive active treatment (AAP) if deemed appropri-
ate. However, patients who had already received AAP in
the first-line are not eligible for re-treatment with AAP
post-docetaxel. After all treatment options had been
explored and disease has progressed, patients then enter a
palliative stage. Hence, the model effectively compares
AAP followed by docetaxel and subsequent treatments (not
including AA) with watchful waiting (including BSC)
followed by docetaxel and subsequent treatments (includ-
ing AA).
The model was primarily populated using the COU-AA-
302 trial (third interim analyses) [13–15] and consisted of a
total of 17 prediction equations for estimating time to
treatment discontinuation (TTD), time to treatment start,
time to death within the various treatment phases, and
(disease) status of the patient at different phases. To esti-
mate these prediction equations, study data of 902 patients
were used [83 % of the intention-to-treat (ITT) population,
which consisted of 1088 patients]. Various covariates were
included in these prediction equations, chosen largely on
the basis of statistical significance, although the ERG noted
that non-significant covariates were inconsistently included
in some cases. These prediction equations were combined
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with the profile/characteristics of individual patients to
estimate the exact treatment path, including duration in the
various treatment phases, and survival.
Although utility data were obtained from the COU-AA-
302 trial (indirectly via mapping FACT–P results) [13–15],
utility values in the base-case model came from a UK
mCRPC utility study (online survey among 163 patients).
Only the base case on-treatment utility increment of AAP
over BSC (pre-docetaxel) was obtained from the COU-AA-
302 trial [13–15]. For all other treatment phases, FACT–P-
mapped utilities were included in a scenario analysis. AEs
were not separately taken into account in the utility score
as the safety profile of AAP and BSC was considered
similar, and all other effects of treatment (e.g. docetaxel)
on HRQoL would have been captured in the treatment-
phase specific utility value. No utility increment was
applied for post-docetaxel AAP treatment, unlike STA259
(considering AAP for mCRPC previously treated with
docetaxel) [5]. For advanced/metastatic prostate cancer,
utility values typically vary between 0.50 and 0.87 [18].
Costs (2012–2013 price level) were considered from an
NHS and Personal Social Services perspective. Moreover,
costs were subdivided into treatment costs, costs of
scheduled medical resource utilisation (MRU), and costs of
unplanned MRU (including AEs). Monthly treatment costs
for AAP are considerably higher than the cost for BSC,
which was represented by prednisolone 10 mg daily and is
therefore negligible. The monthly cost of docetaxel,
including administration costs, is £1550. Scheduled MRU
was assessed by means of a survey among 53 UK oncol-
ogists, with questions on total outpatient visits, scans, and
laboratory tests. For AAP-treated patients, both pre- and
post-docetaxel, a higher MRU is applied until 3 months
after the start of treatment because they require additional
monitoring. Unplanned events while on treatment were
estimated, where possible, based on the COU-AA-301
[19, 20] and COU-AA-302 [13–15] trial data. However,
since these trials did not contain unplanned MRU data for
BSC (pre- and post-docetaxel and palliative phase), or
docetaxel, unplanned MRU of proxy groups had to be used
for these phases in the model. For pre- and post-docetaxel
phases, treatment of AEs was considered to be included in
the unplanned MRU. Costs of incremental grade 3 or 4 AEs
for docetaxel compared with AAP were assigned sepa-
rately. Resources and medication used for treating these
AEs were assessed by means of expert opinion.
The base-case deterministic incremental cost-effective-
ness ratio (ICER) for AAP versus BSC was £46,722 per
QALY gained. One-way sensitivity analyses indicated that
the most influential parameters are likely to be the post-
ADT baseline utility and the discount rate for the health
benefits. In addition, scenario analyses were performed on
various assumptions. When excluding the PAS, and also in
the scenario where FACT–P mapping utilities were used
instead of EQ-5D from the patient utility study, this
resulted in ICERs above £50,000 per QALY gained. For all
other scenarios, ICERs would be lower than £50,000 per
QALY gained.
3.4 Critique of Cost-Effectiveness Evidence
and Interpretation
The critical appraisal of the company’s economic evalua-
tion by the ERG highlighted a number of concerns:
AAP
BSC 
(pre-docetaxel)c
Docetaxeld
BSC 
(post-docetaxel)e
BSC (PP)b
BSC 
(pre-docetaxel)c
Docetaxeld
BSC 
(post-docetaxel)e
AAP
(post-docetaxel)
Fig. 1 Visual representation of the DES model (see Figs. 5.1 and 5.2
from the ERG report [3] for more details). DES discrete event
simulation, AAP abiraterone acetate in combination with prednisone/
prednisolone, BSC best supportive care, PP placebo plus prednisone/
prednisolone, ERG Evidence Review Group, ECOG Eastern Coop-
erative Oncology Group, PS performance score. a Patients could die
in all stages of the model, except during AAP, BSC (PP), and post-
docetaxel treatment. If patients die, they firstly go through the ‘BSC
before death’ phase involving palliative care, until death. This
consists of the ‘end-of-life’ phase where patients are near death and
will not receive additional active treatments that may impact survival,
but instead are managed for their pain or other symptoms. b BSC (PP)
involves active monitoring without active treatments that impact
survival (patients are still receiving treatments that palliate symptoms
of disease, e.g. corticosteroids). c Patients for whom pre-docetaxel
treatment was discontinued or in whom disease was progressed were
monitored in a BSC (pre-docetaxel) phase prior to commencing
docetaxel treatment. No active treatment that impacted survival was
provided during this phase (although patients are still receiving
treatments that palliate symptoms of disease). d Patients started
docetaxel only if ECOG PS score \2 (assumed to correspond to
Karnofsky PS score C60 %). Otherwise, patients moved to ‘BSC
before death’ until death. e This phase involves no active treatment
that has shown to impact overall survival while patients are still
receiving treatments that palliate symptoms of disease. Furthermore,
it was assumed that if patients received AAP prior to docetaxel they
would not be eligible for AAP retreatment post-docetaxel, whereas
BSC patients were allowed to receive AAP post-docetaxel
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• deviation from the decision problem defined in the
scope;
• overly complicated model that lacks transparency;
• using the analysable dataset instead of the ITT
population;
• inconsistencies in the estimation of prediction
equations;
• not fully incorporating the impact of AEs;
• on-treatment utility increment for post-docetaxel AA;
• short post-docetaxel survival
The main deviation from the decision problem defined
in the scope [6] was that docetaxel is not included as a
comparator. However, as the indication is men with
mCRPC in whom chemotherapy is not yet clinically indi-
cated, it seems reasonable that docetaxel is not considered
as a comparator.
Regarding the model structure, the ERG does not
believe that a DES model, simulating individual patients by
means of 17 prediction equations, was the most transparent
approach possible to address the decision problem defined
in the scope. Transparency is a key aspect of modelling and
in this specific case a more transparent model would be
more convenient for an external reviewer to assess face
validity and internal validity of the model. Moreover, a
more transparent model would have allowed the ERG
much more flexibility in performing additional analyses.
The prediction equations were estimated based on what
the company referred to as the analysable patient sample,
which is a subset (n = 902) of the ITT population
(n = 1088). The company argued that the ITT population
could not be used for estimating prediction equations
because baseline data were missing for a number of
patients. However, this approach introduced bias in favour
of AAP for both TTD and OS (as OS is dependent on
TTD). This is illustrated in Fig. 3 in the company’s
response to NICE’s request for additional information (see
Janssen [16]). Therefore, the ERG would have preferred an
approach in which the prediction equations were based on
the ITT population and imputing any missing baseline data
or, alternatively, to use treatment as the only covariate.
In addition, the process of estimating the prediction
equations was not consistent. For instance, the equation for
‘time from AAP/BSC (PP) end to death’ was, unlike all
other prediction equations, estimated separately by arm,
while for all other equations, treatment was included as a
covariate. Although requested by the ERG in the clarifi-
cation phase, the company could not provide a convincing
reason for using this procedure [16]. Furthermore, candi-
date covariates varied between prediction equations. A
rationale for selecting the candidate covariates was absent.
In addition, interaction terms were sometimes included in
an equation despite a non-significant p-value. Adding
covariates or interaction terms even when they were not
statistically significant for ‘time to AAP/BSC (PP) end’ and
‘time from post-docetaxel treatment end to death’ could not
be regarded as conservative as this increased the effec-
tiveness of AAP versus BSC in both instances (see
Sect. 5.2.6 of the ERG report [3] for more details).
Therefore, the ERG would have preferred a well-defined
and consistently applied procedure on whether or not to
stratify, and on including covariates and interaction terms.
Without such a procedure, it is difficult to rule out bias
caused by these elements.
Although AAP seemed to be associated with more grade 3
and 4 AEs, the company argued that, because AAP and BSC
have a similar safety profile, differential AE utility values for
AAP andBSCwere not indicated, and the on-treatment utility
gain for AAP versus BSC would capture all relevant differ-
ences. The only way AEs were explicitly taken into account
was in the costs of treating AEs during the docetaxel phase.
Therefore,AEswere not incorporated separately inHRQoL in
anyway, norwere they incorporated in the costs in the pre- and
post-docetaxel phases. In the clarification phase, the ERG
requested an additional analysis, removing the on-treatment
utility gain and using perAEutility decrements, aswell as pre-
and post-docetaxel AE treatment costs [16]. The ICER in this
additional analysis increased to £50,880, indicating that not
explicitly incorporating AE utility decrements is not conser-
vative. In addition, SREs were not considered by the com-
pany, whereas they were included in STA259 [5] and
mentioned in the scope [6]. Given that COU-AA-301 [19, 20]
demonstrated that, for post-docetaxel AAP, time to SREs was
improved compared with placebo, it can be questioned whe-
ther not including SREs in the present submission can be
considered conservative.
Unlike in STA 259 [5], no post-docetaxel on-treatment
utility increment for AAP was applied in the current
assessment. The company argued that applying a post-do-
cetaxel utility increment of 0.046 (derived from COU-AA-
301 trial data) would be double counting since the majority
of patients in the UK mCRPC utility study were assumed to
have already been receiving AAP in this setting, and
therefore the on-treatment utility gain was captured directly
in the utility value. However, the ERG could not see any
reason why this would not still allow the use of a differ-
ential utility value, and requested an analysis incorporating
a BSC on-treatment decrement. The company performed
this analysis, together with a higher post-docetaxel baseline
utility, to be more in line with STA259 [5] (also requested
by the ERG). This analysis resulted in an ICER of £47,936
per QALY gained. The ERG therefore concluded that the
results are rather robust with respect to these changes in
utility values post-docetaxel.
Post-docetaxel survival in the current model seems very
low compared with STA259 [5]. This is difficult to explain
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given that STA259 considered patients who were in the
post-docetaxel phase.
3.5 Additional Work Undertaken by the ERG
Due to the abovementioned concerns, the ERG questioned
the validity of the ICER provided by the company. The
ERG was able to resolve some of the issues highlighted by
using an on-treatment utility for post-docetaxel active
treatment, and non-stratified prediction equations based on
the ITT population, using treatment as the only covariate.
This resulted in an ICER of £57,688 per QALY gained for
the ERG base case (Table 1).
ICERs calculated in the additional sensitivity analyses
performed by the ERG ranged between £56,671 and £74,803
per QALY gained. Assuming post-docetaxel survival is
equal to that in STA259 [5] (by adjusting the coefficients for
‘time from post-docetaxel treatment discontinuation to
death’) resulted in an ICER of £65,515 per QALY gained.
Finally, replacing the log-logistic distributions (two predic-
tion equations) with Weibull distributions resulted in an
ICER of £74,803 per QALY gained (Table 1).
3.6 End-of-Life Criteria
NICE end-of-life supplementary advice should be applied
in the following circumstances and when all the criteria
referred to below are satisfied [21]:
• the treatment is indicated for patients with a short life
expectancy, normally less than 24 months;
• there is sufficient evidence to indicate that the treatment
offers an extension to life, normally of at least an
additional 3 months, compared with current NHS
treatment;
• the treatment is licensed, or otherwise indicated, for
small patient populations.
With regard to the first criterion, the CS [2] showed that
after 24 months, approximately 63 % of subjects in the
control group are still alive, and that the median survival is
30.1 months (95 % CI 27.3–34.1). Therefore, it was unli-
kely that life expectancy in this patient group would be less
than 24 months. According to the company, patients in the
trial were likely to have gone on to receive other clinical
trial technologies post-docetaxel, and therefore the survival
observed for these patients was probably not reflective of
the average mCRPC patient in the UK. However, as far as
the ERG was aware, the ‘short life expectancy, normally
less than 24 months’ was based on the normal treatment
options available for these patients without the intervention
under assessment.
With regard to the second criterion, the company pro-
vided median survival estimates, but not mean survival, in
the CS [2]. In the clarification letter, the ERG asked the
company to provide the mean survival in the BSC group in
COU-AA-302 for the overall population and for the sub-
group of patients from UK centres, and the mean survival
Table 1 Overview of additional analyses undertaken by the ERG (reported in original ERG report)
Technology Incremental costs (£) Incremental QALYs ICER, £/QALY gained
Company base case 26,404 0.57 46,722
Recalculated company base casea 26,423 0.57 46,756
Post-docetaxel on treatment utilityb 26,423 0.56 46,952
Updated prediction equationsc 24,757 0.43 57,337
ERG base cased 24,757 0.43 57,688
Additional sensitivity analyses (based on ERG base case)
Remove cabazitaxel negative treatment effect 24,821 0.44 56,671
Equal post-docetaxel survival compared with STA259 24,159 0.37 65,515
Weibull instead of log-logistic 19,620 0.26 74,803
Weibull instead of log-normal 24,565 0.43 57,202
QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio, ERG Evidence Review Group, STA NICE single technology
appraisal, AA abiraterone acetate, BSC best supportive care, CS company submission
a The ERG could not replicate the results presented in the CS using the economic model provided by the company. This minor deviation was
later explained by a typographical mistake prior to submission by the company, resulting in higher docetaxel adverse event costs being double
counted when the ERG ran the model
b A disutility of 0.046 was applied in the post-docetaxel phase for patients not receiving active treatment (i.e. receiving BSC instead of AA)
c Prediction equations based on the intention-to-treat population, and including treatment as the only covariate, were used (based on the ‘302
mode Parametric Functions Parameters’ file provided by the company in response to clarification question B4a)
d A combination of the two scenarios mentioned above
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gain of AAP compared with BSC in COU-AA-302 for the
overall population and for the subgroup of patients from
UK centres. The company responded that they were unable
to answer these questions (see company response to request
for clarification from the ERG [16]).
With regard to the third criterion, it is likely that the
treatment is indicated for a small patient population.
3.7 Conclusion of the ERG Report
An important question in this appraisal was, according to
the ERG, whether AAP followed by docetaxel is more
effective than BSC followed by docetaxel. In the COU-
AA-302 trial, 239 of 546 (43.8 %) AAP patients and 304 of
542 (56.1 %) PP patients received docetaxel as subsequent
therapy, following AA or placebo [2]. The results for this
specific group of patients were not presented in the CS;
therefore, the ERG asked the company to provide these
data in the clarification letter. However, these data were
presented as commercial-in-confidence and can therefore
not be reported here.
The ERG was able to resolve some of the issues high-
lighted in the cost-effectiveness section of the report, and
calculated an ICER of £57,688 per QALY gained for the
ERG base case. This included using the ITT population,
with treatment as the only covariate, for the estimation of
the prediction equations. Ideally, the ERG would have
preferred an approach in which the prediction equations are
based on the ITT population and imputing any missing
baseline data to be able to consistently use additional
covariates. However, the ERG was unable to provide these
analyses as it did not have access to the individual patient-
level data. Moreover, the ERG acknowledged that uncer-
tainties remain concerning the reliability of the cost-ef-
fectiveness evidence, which could neither be handled in the
ERG base case nor could a sensitivity analysis be provided
to estimate the impact of these issues on the results. These
issues include not including the possibility of dying during
AAP/BSC treatment and post-docetaxel active treatment,
not using differential costs and utilities for all AEs for all
treatment phases (including SREs), and lack of empirical
data to calculate resources and costs for most of the
treatment phases.
3.8 Addenda Submitted by the ERG
Not including separate additional analyses requested by
NICE, the ERG submitted four addenda [4] (upon request),
in response to questions raised by the AC, to additional
data provided by the company and to a new PAS submitted
by the company. Moreover, this appraisal entailed, in total,
five AC meetings (ACMs), two ACDs, and two FADs. For
clarity, a timeline is provided in Table 2.
In its response to the second ACD, the company pro-
vided new cost-effectiveness analyses, including the com-
pany’s base case, resulting in an ICER of £28,563 per
QALY gained. The following changes were applied to the
company’s original base case to obtain this new base case:
• a new PAS was incorporated;
• the docetaxel drug price was reduced by 20 %;
• a utility increment of 0.021 was applied to the post-
docetaxel active treatment phase of the model.
The new PAS included a permanent reduction in the official
list price for AA by 21.5 %, resulting in a price of £2300 per
30-days pack [22]. In addition, as part of the new PAS, the
drug acquisition costs of AA would be rebated to the NHS
after 10 months of treatment for each individual patient.
In addition to the new base case, the company included a
piecewise curve (log-logistic ? Weibull for extrapolation
[4]) for time to first-line TTD instead of using the log-
logistic distribution only. This was done since it is unclear
whether the long tail of the log-logistic distribution is
clinically plausible. This analysis also included arbitrarily
limiting TTD to a maximum of 1000 days for BSC only,
and resulted in an ICER of £32,849 per QALY gained.
The ERG base case included some additional adjust-
ments to the original company base case:
• Including aPASadministration fee aspart of the newPAS.
• Using the old PAS for BSC (post-docetaxel AA) and
the new PAS for AA (pre-docetaxel AA). This was
preferred because, in case the current appraisal does not
recommend AA before docetaxel, the old PAS would
be maintained for AA after docetaxel.
• Assuming that AA non-compliance does not lead to
recoverable drug costs.
• Applying a utility increment of 0.046 (consistent with
STA259 [5]) to the post-docetaxel active treatment
phase of the model.
• Using the prediction equations based on the ITT
population, including treatment as the only covariate.
Using these additional adjustments resulted in an ICER
of £38,061 per QALY gained for the ERG base case and
£54,091 per QALY gained when also using the piecewise
curve for TTD (without the arbitrary TTD cap of
1000 days for BSC) [see Table 3 for an overview of
selected analyses based on the new PAS].
4 Key Methodological Issues
The ERG raised several issues regarding the cost-effec-
tiveness analyses methods and assumptions presented by
the company. The impact of some of these issues on the
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estimated ICER was examined by the ERG and, if appli-
cable, adjusted in the ERG base case. The issue that
appeared to have the most impact on the ICER was using
the ITT population and the consistent selection of (candi-
date) covariates and interaction terms for estimating the
prediction equations. This was salvaged in the ERG base
Table 2 Timeline
Date Event Comment
December
2012
Marketing authorisation AA
extended to pre-docetaxel
April 2014 ACM 1 ACD 1: not recommended (AC concluded that all the ICERs estimated by both the company
and the ERG fell substantially above the range normally considered cost effective, i.e.
£20,000–30,000 per QALY gained)
June 2014 ERG addendum 1 ERG response to comments raised during ACD consultation on the benefit of delaying
chemotherapy
June 2014 ACM 2 FAD 1: not recommended (AC concluded that all the ICERs estimated by both the company
and the ERG fell substantially above the range normally considered cost effective, i.e.
£20,000–30,000 per QALY gained)
September
2014
Appraisal suspended pending
revised PAS
April 2015 ERG addendum 2 ERG response to new PAS
October
2015
ACM 3 Request new data from company
November
2015
ERG addendum 3 ERG response to the company’s response to NICE’s request for additional information
November
2015
ACM 4 ACD 2: not recommended (AC most plausible ICER likely between £35,500 and £59,600
per QALY gained)
January
2016
ERG addendum 4 ERG response to the company’s response to ACD
February
2016
ACM 5 FAD 2: recommended (AC most plausible ICER likely between £28,600 and £32,800 per
QALY gained; see Sect. 5)
AA abiraterone acetate, ACM Appraisal Committee Meeting, ACD Appraisal Consultation Document, AC Appraisal Committee, ICER incre-
mental cost-effectiveness ratio, ERG Evidence Review Group, QALY quality-adjusted life-year, PAS patient access scheme, FAD Final Appraisal
Determination, NICE National Institute for Health and Care Excellence
Table 3 Selected additional analyses undertaken by the company and the ERG (using the new PAS)
Technology Incremental
costs (£)
Incremental
QALYs
ICER, £/QALY
gained
Company base case 16,055 0.56 28,563
Company base case ? piecewise curve 15,855 0.48 32,849
ERG base casea 15,089 0.43 35,486
ERG base caseb 16,098 0.43 37,859
ERG base casec 16,184 0.43 38,061
ERG base case ? piecewise curve 15,938 0.31 51,026
ERG base case ? piecewise curve (without arbitrarily limiting TTD to a maximum of
1000 days for BSC only)
15,908 0.29 54,091
PAS patient access scheme, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio, ERG Evidence Review Group, TTD time
to treatment discontinuation, BSC best supportive care, AA abiraterone acetate, AAP AA in combination with prednisone/prednisolone
a ERG base case, including the new PAS for both BSC (post-docetaxel AA) and AAP (pre-docetaxel AA), not including the PAS administration
fee (for the new PAS)
b ERG base case, including the old PAS for BSC (post-docetaxel AA) and the new PAS for AA (pre-docetaxel AA), not including the PAS
administration fee (for the new PAS)
c ERG base case, including the old PAS for BSC (post-docetaxel AA) and the new PAS for AA (pre-docetaxel AA), including the PAS
administration fee (for the new PAS)
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case by using the ITT population to estimate the prediction
equations, and including treatment as the only covariate.
Ideally, the approach to estimate the prediction equations
would be based on the ITT population and imputing any
missing baseline data to be able to consistently select
covariates and/or interaction terms.
The ERG acknowledged that there are remaining
uncertainties that could not be examined and/or included in
the ERG base case, including censoring for BSC patients
after sequential treatment with AAP and cabazitaxel, not
including the possibility of dying during AAP/BSC treat-
ment and post-docetaxel active treatment, not using dif-
ferential costs and utilities for all AEs for all treatment
phases, and no empirical data to calculate resources and
costs for most of the treatment phases. Moreover, during
the ACMs, the face validity of the economic model was
questioned because clinical experts stated that patients
switch from first-line treatment to docetaxel within 1 week
of disease progression, whereas this was estimated to be
over 5 months in the model (see second ACD and FAD
[4]).
5 National Institute for Health and Care
Excellence (NICE) Guidance
In March 2016, the AC produced the final guidance, stating
that AAP is recommended, within its marketing authori-
sation, as an option for treating mCRPC:
• In people who have no or mild symptoms after ADT
has failed, and before chemotherapy is indicated.
• Only when the company rebates the drug cost of AA
from the eleventh month until the end of treatment for
people who remain on treatment for more than
10 months.
5.1 Consideration of Clinical Effectiveness
The AC concluded that AAP delayed disease progression
and improved OS compared with placebo, but that there
was uncertainty about the extent of the survival benefit.
The AC stated that as chemotherapy can reduce a person’s
quality of life, treatments delaying the need for
chemotherapy are highly valued by patients.
The AC noted that AAP was innovative and that the
utility values in the model may not fully capture the benefit
to patients of delaying cytotoxic chemotherapy.
The AC concluded that current mean life expectancy for
chemotherapy-naı¨ve mCRPC was unlikely to be less than
24 months, and AAP at this stage in the treatment pathway
did not meet the end-of-life criterion for short life
expectancy.
5.2 Consideration of Cost Effectiveness
The AC noted that the scope (issued by NICE in 2012)
included docetaxel as a comparator, but the company did
not include docetaxel as a comparator because the mar-
keting authorisation states that AA should be used for
people for whom chemotherapy is not yet indicated. The
AC agreed that not incorporating docetaxel was
appropriate.
The AC stated that a DES model was not unreasonable,
but that the company’s model was particularly complex
and lacked transparency, which made it difficult for the
ERG to validate and critique, and for the AC to determine
the plausibility of the model outcomes.
In principle, the AC agreed with the ERG that it is
preferable to use the ITT population for modelling because
this reduces the risk of bias. However, in this specific case,
the AC agreed with the company that it was appropriate to
use the full covariate subgroup rather than the ITT
population.
With regard to the 17 equations predicting time to
events or disease status in the DES model, the AC noted
that the company made a large number of judgements when
determining which covariates to include and which para-
metric distribution to choose for extrapolation. The AC
noted that, for two equations, the company had not fol-
lowed its own statistical plan when choosing covariates,
and the AC agreed with the ERG that this could introduce
bias to the model.
For estimation of TTD for the duration of the trial
period, the AC stated that the log-logistic curve was the
best fit to the trial data (used in the base case of both the
company and the ERG). However, it was noted that the
log-logistic curve predicted that some patients remained on
AAP for a long time (4 % took AAP for 8 years or more),
which could not be supported by trial data. The AC noted
that the Weibull curve predicted that fewer patients remain
on AAP in the long term, and the piecewise curve gave
predictions that were in-between the log-logistic and
Weibull curves. However, in this latter analysis, the com-
pany assumed that all patients stopped having BSC at
1000 days, and the AC was concerned that this assumption
may not be clinically plausible. The AC concluded that, for
predicting TTD, it is preferable to use either the log-lo-
gistic or piecewise curve.
The AC discussed post-docetaxel survival estimates of
the DES model. It was noted that the company had not used
data from TA259 [5] to check the validity of its model in
the current appraisal. It also noted that the modelled post-
docetaxel survival times were shorter in the current
appraisal (based on data from COU-AA-302 [13–15]) than
in TA259 [5] (based on data from COU-AA-301 [19, 20]).
The AC was aware that the ERG carried out a scenario
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analysis in which it fixed post-docetaxel survival to be the
same as in COU-AA-301, and this subsequently increased
the ICER. The AC heard from the company that, although
the estimates from COU-AA-301 came from a larger
sample of patients, it did not consider these data to be
relevant for the current appraisal because the population in
COU-AA-301 was different from that in COU-AA-302. On
balance, the AC concluded that it was appropriate to use
COU-AA-302 to estimate post-docetaxel survival times.
Nonetheless, it was also concluded that uncertainty about
the modelled survival times persisted because only a small
number of patients from COU-AA-302 contributed data to
this phase of the model.
The AC understood that the company’s base-case model
used 98 % of the cost of the licensed dose of AA, as in
COU-AA-302 [13–15] patients took, on average, 98 % of
the licensed dose. The AC considered that the full cost of
the licensed dose of AA should be included in the model as
the cost of unused tablets was unlikely to be recovered.
Additionally, it was noted by the AC that the costs of
administering the PAS, although low, had not been inclu-
ded in the company’s base case, and considered that these
costs should have been included. Moreover, the AC
acknowledged that the two PASs would not and could not
exist at the same time. Nonetheless, it concluded that it was
appropriate to include the existing PAS for BSC and the
new complex PAS for AA for the purposes of decision
making, and it acknowledged that using this approach in a
scenario analysis had a modest impact on the ICER. The
AC noted that the company’s assumptions relating to these
costs favoured AA, but that including the AC preferred
assumptions increased the ICER for AA, P compared with
BSC, only slightly.
6 Conclusions
This paper describes the STA on AAP for the treatment of
chemotherapy-naı¨ve mCRPC. The evidence suggests that
AAP is an effective treatment option for the treatment of
chemotherapy-naı¨ve mCRPC. The preferred analysis of the
ERG showed that AAP might not be cost effective, but the
AC did not agree with the ERG assumption to use the ITT
population and considered that the most plausible ICERs
were within the range that could be considered cost
effective, and hence recommended AAP for chemotherapy-
naı¨ve mCRPC. However, it should be noted that this STA
did not consider enzalutamide, which is now recommended
as an option for treating chemotherapy-naı¨ve mCRPC, and
hence no statements can be made regarding the cost
effectiveness of AAP versus enzalutamide for this
population.
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